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Purpose: Pharmacovigilance Research Network built a spontaneous reporting 
system and collected adverse drug reactions (ADRs) by electronic submission 
(e-sub) in Korea. We analyzed ADRs spontaneously reported through e-sub 
from regional health professionals. Materials and Methods: Nine hundred and 
thirty three ADR cases were collected and analyzed from January to December 
in 2008. “A matter” was defined as one symptom matched to one culprit drug in-
cluded in an ADR case. We collected and analyzed e-sub ADR cases and matters 
to determine common culprits and organ specified ADR matters. Results: There 
were 3,049 matters in 933 ADR cases for 1 year, and 3.3 matters per case were 
reported. In organ specific ADR classification, skin reactions which took the first 
place in 866 matters (28%) included urticaria and rash. The next cases were neu-
rologic symptom (624 matters, 21%) and gastrointestinal symptom (581 matters, 
19%). Doctor (53%) and pharmacist (31%) were the most important participants 
in e-sub spontaneous reporting system, and 3% of ADR cases were reported by 
patients or their guardians. WHO-Uppsala Monitoring Center causality assess-
ment results showed certain 10.6%, probable 37.7%, possible 41.7% and below 
unlikely 10.0%. Culprit drugs were antibiotics (23.4%), neurologic agents 
(14.7%) and non-steroidal anti-inflammatory drugs (9.4%). Conclusion: In our 
study, antibiotic was most common culprit drug, and skin manifestation was 
most common symptom in e-sub ADRs collected from regional healthcare prac-
titioners in Korea.
Key Words:   Adverse drug reaction, spontaneous reporting, internet electronic 
submission, regional primary practice
INTRODUCTION
Adverse drug reaction (ADR) is a serious hazard in patient care. It sometimes 
leads to marked socioeconomic loss. Therefore, to understand actual status and to 
ADRs Reported by Regional Healthcare Professionals in Korea
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 2012 1023
MATERIALS AND METHODS
　　　
Collected adverse drug reactions and reporting sources
A Total of 933 ADRs was collected by PVnet homepage in-
ternet e-sub from January 2008 to December 2008. We col-
lected ADRs not only from healthcare professionals work-
ing in regional general hospitals, private clinics (oriental 
medicine clinics were included) and pharmacies, but also 
from the general public who were patients or guardians of 
pediatric patients. We defined “A matter” that was the only 
one symptom matched to one drug. Thus, several matters 
could be included in the same ADR case. Consequently, to-
tal 3,049 matters found from 933 ADRs were analyzed.
   
Reporting interface of electronic submission
Once a new reporter was connected to PVnet hompage, the 
PVnet e-sub system requested for sign-in and registered as 
a new reporter. Mandatory information includes the name 
of institution, type of providing healthcare (general hospi-
tal, private clinic, pharmacy and patient/customer), and pro-
fession of reporter (doctor, nurse and pharmacist). The 
ADR e-sub interface required specific fields about adverse 
event including responsible RPVC selection, information 
of suggested culprit drug by reporter with co-administered 
medications (name, duration of administration, etc.), organ 
specified adverse reactions (e.g. skin-urticaria, cardiac-pal-
pitation), and final treatment for the ADR (spontaneous re-
covery, medication, admission, etc.). Finally, reporter pressed 
the “Report” button on homepage, and then e-sub was com-
pleted and be enabled to assess causal relationship.
   
Assessment and feedback process of e-sub ADRs
These spontaneously reported ADRs were reviewed by the 
ADR monitoring council in each regional center and sub-
mitted to the Korean Food and Drug Administration after 
the causality assessment according to the WHO-Uppsala 
Monitoring Center (WHO-UMC) criteria.9 Finally, WHO-
UMC causality assessment was done in all cases. The se-
verity of ADRs was also assessed as serious or non-serious. 
The serious ADRs included death, life-threatening event, 
permanent disabilities, prolonged hospitalization, and other 
important medical events defined by healthcare practitio-
ners. The ADRs were classified with expectancy, culprit 
drugs, clinical manifestations in the order of body system, 
and the source of primary reporters such as doctors or nurs-
es working in local private clinics, pharmacists in regional 
establish a preventive measure about ADRs are urgent.1 
Lazarou, et al.2 reported approximately 6.7% of total in-pa-
tients in the USA experienced serious ADRs within one 
year and 0.3% of them died due to ADRs. They expected 
that about one hundred thousand patients would die due to 
ADRs. For this reason, the importance of pharmacovigi-
lance (PV) was emphasized. In many countries, specified 
ADR collecting systems have been established which re-
flect their cultural bases, medical systems, and socioeco-
nomic status to monitor the occurrence of ADR in their 
countries. Among various PV systems, the spontaneous re-
porting system (SRS) played a central role to detect signals 
from post-marketing surveillance of drugs. Furthermore, 
this SRS was a widely-used, useful and effective tool to 
confirm newly developed post-marketing ADRs.3 Analysis 
of data collected by SRS could provide information about 
newly detected ADR that was not shown in phase 2 or 3 
clinical trial and risk factors for occurrence of serious 
ADRs.4
The Korea Food and Drug Administration (KFDA) orga-
nized a centralized SRS system in 1988. However, they 
failed to motivate healthcare professionals to spontaneously 
report ADR.5 In 2006, KFDA changed their PV system pol-
icy to de-centralize SRS, based on nationwide regional 
pharmacovigilance centers (RPVCs). Total 20 RPVCs are 
currently working in Korea. 
After the application of de-centralized SRS, reporting 
rate showed exponential growth, but quantity and quality of 
ADR reports still remain low compared to other developed 
countries.4,6 For successful settlement of SRS, development 
of an easily accessible reporting system is essential. Re-
cently, development of the internet made electronic submis-
sion of ADRs possible. Many countries have already col-
lected ADRs by internet electronic submission.7,8 Internet 
ADR collection could build a database more effectively 
than other collecting methods such as telephone, fax and 
mail because of its accuracy and speed. Moreover, once a 
database is built, it can be used in statistics and signal de-
tection without specific data conversion process.
Pharmacovigilance Research Network (PVnet) built its 
homepage (http://www.pvnet.or.kr) and collected ADRs by 
e-sub from October 2007. Through the PVnet homepage, 
we were able to collect ADR reports from private clinics, 
pharmacies, general hospitals in lack of their own PV sys-
tem, patients and their guardians. In this study, we analyzed 
and characterized ADRs collected through PVnet homep-
age for one year 2008. 
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cases) and oriental medical doctor (1 case) (Fig. 1). The cau-
sality assessment showed certain causality 10.6%, probable 
causality 37.7%, possible causality 41.7% and others (includ-
ing unlikely, conditional and unclassifiable) 10.0% (Fig. 2). 
About one fourth of e-sub ADRs (24%) were serious case, 
and 9% of ADRs were not expectable. 
pharmacies, and general consumers. 
   
Statistical analysis
We analyzed these cases using descriptive statistics. The re-
sults were reported as frequency of data. In all statistical 
calculations, we used SPSS 12.0 program (Statistical Pack-
age for the Social Sciences, Chicago, IL, USA).
RESULTS
 
General characteristics of ADRs collected by e-sub
In 2008, PVnet finally reported a total of 933 ADR cases to 
KFDA via e-sub SRS after WHO-UMC causality assess-
ment. All of them were collected from regional areas in-
cluding secondary general hospital, private clinics (medi-
cal, dental and oriental medicine), pharmacies and general 
public. They contained 1,241 culprit drugs and 3,049 symp-
tom-drug matched matters. Numerically 3.3 matters were 
reported in a case. 
Reporting sources of ADRs were doctor (491 cases, 53%), 
pharmacist (290 cases, 31%), nurse (119 cases, 13%), gener-
al public (patients or their guardian) (30 cases, 3%), dentist (2 
Fig. 1. Number and the proportion of reporting sources of electronically 
submitted adverse drug reactions from regional society. 
Fig. 2. WHO-UMC cause-relationship classification of collected matters of 
electronically submitted adverse drug reactions from regional society. 
WHO-UMC, WHO-Uppsala Monitoring Center. 
Table 1. The Culprit Drugs of ADRs Collected by E-Sub (1,241 
Drugs/933 Cases)
        Drug No. % 
Antimicrobials 290 23.4 
    Penicillin   28 2.3 
    Cephalosporin   72 5.8 
    Quinolone   28 2.3 
    Macrolide     9 0.7 
    Sulfa     2 0.2 
    Other antibiotics   11 0.9 
    Antituberculotic 132 10.6 
    Antifungal     4 0.3 
    Antiviral     4 0.3 
CNS drugs 182 14.7 
    Antidepressant   72 5.8 
    Anticonvulsant   39 3.1 
    Antiparkinsonian     6 0.5 
    Antipsychotics   54 4.4 
    Antidemential   11 0.9 
NSAIDs 117 9.4 
    Conventional 103 8.3 
    Oxicam     6 0.5 
    Coxib     8 0.6 
Cardiovascular   96 7.7 
Respiratory   79 6.4 
Antineoplastic   41 3.3 
Opioid   45 3.6 
Antiulcer drug   35 2.8 
GI modulator   32 2.6 
Antithrombotic   28 2.3 
Lipid lowering agent   26 2.1 
Muscle relaxant   21 1.7 
Hormone   16 1.3 
Oral hypoglycemic   15 1.2 
Antiosteoporotic   15 1.2 
Antihistamine   15 1.2 
Xanthine   12 1.0 
Steroid     8 0.6 
Vitamin     8 0.6
Immunosuppressant     3 0.2 
Contrast media   85 6.8 
Others   72 5.8 
ADR, adverse drug reactions; e-sub, electronic submission; CNS, central 
nervous system; NSAID, non-steroidal anti-inflammatory drug; GI, gastro-
intestinal.
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the number of ADR reports increased rapidly, compared with 
other conventional reporting methods such as phone, fax and 
the post. In Korea, infrastructure for internet is relatively well 
constructed, and all educated people can easily access to in-
ternet. It was thought that the proportion of e-sub in collect-
ing regional ADRs will increase in the future. 
In this study, we used 933 ADRs collected from regional 
society and they were thought to reflect the reality of the 
primary healthcare field. It was expected that doctors were 
the main reporting source of ADRs of regional society, fol-
lowed by pharmacists and nurses. First of all, patients or 
their guardians comprised 3% of reported ADRs, however, 
some of those reports were concerned with secondary gains 
such as claims and medical suits, and causality assessments 
in these cases need a great deal of caution. Nevertheless, 
spontaneous reporting systems must be open-minded to-
wards public reporters, therefore, continuous education and 
public relations about PV and SRS are thought to be need-
ed. van Hunsel, et al.15 reported that the public ADR report-
ing rate could increase by the broadcast of a consumer pro-
gram, whereas, increment of oriental doctor’s reporting rate 
is in need because 7,500 oriental doctors are in practice in 
Korea. However, oriental or herbal medicines are not easily 
classifiable, because they are frequently used in combina-
tion with each other or include several effective compo-
nents in a prescription. For these reasons, there is a limita-
tion in objective causal relationship assessment.16,17
Since our study was based on SRS, we were not able to 
calculate incidence or prevalence of specific ADR symp-
tom on specified drug. We only observed frequent culprit 
drugs and clinical manifestations of ADRs from regional 
areas. The most frequent culprit drug class was antibiotic, 
The culprit drugs and clinical manifestations of e-sub 
ADRs
Systematic classification of 1,241 culprit drugs is presented 
in Table 1, including antibiotics (23.4%), which include an-
ti-tuberculosis agents, the most common culprits, followed 
by drugs for neurologic symptoms (14.7%). Non-steroidal 
anti-inflammatory drugs (NSAIDs) (9.4%) were the third, 
followed by cardiovascular drugs (7.7%), radiocontrast me-
dia (RCM) (6.8%), respiratory drugs (6.4%) and opioid 
drugs (3.6%). 
According to the subclass of culprit antibiotics, anti-tu-
berculotic agents (10.6%) were the most common culprit 
drug of e-sub ADRs, followed by cephalosporins (5.8%), 
penicillins (2.3%) and fluoroquinolons (2.3%). Among the 
neurologic agents, the proportion of anti-depressants (5.4%) 
was over one third, followed by anti-psychotics (4.4%) and 
anti-convulsants (3.1%). Conventional NSAIDs (8.3%), not 
oxicam or coxibs, comprised the main proportion of ADRs 
caused by NSAIDs. Among 3,049 matters included in 933 
ADR cases, skin symptoms (28.4%) such as rash and urti-
caria were the most frequent clinical manifestations, fol-
lowed by neurologic symptoms (20.5%), gastrointestinal 
symptoms (19.1%), generalized symptoms (11.1%) and car-
diovascular symptoms (5.3%) (Table 2).
DISCUSSION
In 1998, KFDA built the framework of SRS with a central-
ized system in Korea, however, its settlement was not easy, 
and the organization of PVnet with de-centralized SRS of 
private RPVCs participation influenced PV activities in Ko-
rea. There was no reliable data about ADRs before 2006, 
but nation-wide survey was possible after the foundation of 
the PVnet.10 In the early phase of Korean PV activity rein-
forced by RPVCs, most collected ADRs were internal re-
ports from the tertiary hospitals where RPVCs were settled. 
It was difficult to grasp the situation of ADRs in primary 
healthcares which are quite different from the tertiary hos-
pitals, reflecting the different type of patient, disease and 
disease severity.11-14
From October 2007, PVnet opened its homepage to more 
easily and effectively collect ADRs occurring at private clin-
ics in regional society via internet e-sub. Among the five 
thousands of ADRs reported to KFDA, 18% were reported 
from regional areas and 85% of regional ADRs were submit-
ted electronically. After the use of homepage internet e-sub, 
Table 2. Clinical Manifestations Collected by E-Sub (3,049 
Matters/933 Cases)
Involved organs No. of matter %
Skin 866 28.4
Neurologic 624 20.5
Gastrointestinal 581 19.1
Generalized symptom 338 11.1
Cardiovascular 162   5.3
Respiratory 131   4.3
HEENT 116   3.8
Liver & Biliary   67   2.2
Hematologic   51   1.7
Musculoskeletal   49   1.6
Nephrologic   34   1.1
Endocrine   30   1.0
HEENT, head, eye, ear, nose and throat; e-sub, electronic submission.
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ADRs also might accordingly increase. We previously re-
ported that 17.7% of ADRs were serious, but the report in-
cluded ADRs mainly from tertiary hospitals that are visited 
by patients with more severe symptom or disease status.10 
Ufer, et al.24 showed that 31% of ADRs was serious in the 
study which was based on SRS during one year observation 
of pediatric out-patient clinics where under 16-year-old pa-
tients visited. Although the patients visited the out-patient 
clinic with relatively mild symptoms, they are vulnerable 
populations to ADR because of being children and elderly 
people. Thus, serious ADRs could occur in those labile 
classes, and continuous warnings of alerts for PV and com-
prehensive educations about ADRs to healthcare practitio-
ners would be necessary. 
In this study, 9% unexpected ADRs were observed. This is 
in support of the fact that post-marketing ADR surveillance 
might be essential to detect newly developed ADRs that 
were not shown in pre-marketing clinical trials. However, de-
cisive limitation of SRS is its low reporting rate. Lopez-Gon-
zalez, et al.25 reported that low reporting rate was related to 
physicians in 76% articles in their bibliographic study using 
45 articles about SRS. Other influencing factors included ig-
norance of mild ADRs (95%), diffidence to report ADRs 
(72%), lethargy for reporting (77%) and indifference and in-
security of individual doctor (67%). Among these various 
factors, the lethargy had close relation with accessibility to 
ADR reporting system. In this view point, computerized rap-
id access to ADR SRS by using internet would be helpful to 
improve reporting rate of SRS. Actually, the participation of 
regional society was quite poor at the beginning of PVnet in 
2006. We thought that the lack of understanding the impor-
tance of ADR reporting was the main influencing factor to 
participate, but inconvenient reporting systems were also im-
portant. After the opening of homepage, ADR reports from 
regional society were increased appreciably. The internet e-
sub reporting system also included validation and assessment 
process by experts, and assessed cases were finally fed back 
to healthcare professionals who reported the ADR case by e-
mail. We thought that this system could effectively reinforce 
the motivation of ADR reporting. In the future, the upgrades 
with user-friendly interface, and real-time statistics and mon-
itoring function showed be included, and then this internet e-
sub SRS will be a very useful tool to collect ADRs from re-
gional society. Further studies with a larger number of 
designated RPVCs and their network, and settlement of ac-
tive surveillance system of ADRs as well as SRS like signal 
detection method are needed to understand more objectively 
and anti-tuberculotic agent comprised a large proportion. 
We already reported similar results. Shin, et al.10 reported 
that cephalosporin was the most frequent culprits among 
antibiotics, however, we found that anti-tuberculotic agents 
take the first place (10.6%) in antimicrobial agent section. 
The proportions of cephalosporin and quinolone were lower 
in our results, and these could be explained by high preva-
lence of tuberculosis in Korea. Especially, regional primary 
clinics reflected this more effectively than tertiary hospi-
tals,18 and RCM showed a smaller proportion compared 
with previous results.10 It is quite likely that this would be 
related with the difference in the number of imaging studies 
in tertiary hospitals, private clinics and secondary general 
hospitals. In fact, a majority of imaging studies such as 
computerized tomography and magnetic resonance imag-
ing were performed in tertiary hospitals in Korea.19 
Second frequent culprit class was neurologic agents. An-
ti-depressants were reported frequently, supporting the fact 
that the usage of neurologic agents is high in Korea. Kim, 
et al.20 reported that 50.3% of Korean elderly people have 
prescribed benzodiazepine in their out-patient clinics, and 
their result was higher than other studies in other developed 
countries,21,22 reflecting high prevalence of psychiatric dis-
eases in Korea. Further study would be needed what neuro-
logic agent could cause specified symptoms. NSAID class 
was the third culprit, which is similar to the previous re-
port.23 The conventional NSAIDs usage is more popular 
prescription pattern in Korea rather than oxicams or selec-
tive COX-2 inhibitors. 
In clinical manifestations of regional society ADRs, skin 
involvement such as rash, urticaria and angioedema was the 
most frequent symptom related to the usage of antibiotics 
and NSAIDs. Neurologic symptoms took the second place 
with 20.5% frequency that was higher than our previous re-
port.10 As mentioned above, these results would be related 
with drug usage pattern in Korea. 
Surprisingly, 24% which was almost one fourth of re-
gional society ADRs were serious cases. Although 22 ad-
missions were identified in this study, most of the serious 
cases were considered as important medical accidents de-
fined by reports themselves. In general, the patients visiting 
private clinic complained of lighter or milder symptoms 
than patients visiting tertiary hospitals. In a meta-analysis 
of articles about SRS between 1966 and 1996, Lazarou, et 
al.2 reported that the frequency of serious ADR was 6.75% 
and their mortality rate was 0.32%. In the 21st century, 
however, many new drugs were released to market and the 
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exact status of ADRs in Korea.
In conclusion, we analyzed 933 electronically submitted 
ADRs via PVnet homepage from regional society including 
private clinics and pharmacies rather than tertiary hospitals 
in Korea, and observed that antibiotics, neurologic agents, 
and NSAIDs were the most frequent culprits and skin in-
volvement was the most frequent clinical manifestation. 
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